RE:RE:Partnersdamn, too funny that is such a retail post i just had to respond...so first as TST hits $0.39 was it a dead cat bounce or not (who knows not me or you or any other poster, prognosticator, etc.)... so partnering, again no one on this MB has the foggiest idea of whether or not or if never or not...BP will make that decision IMO with only real regard whether they believe MCNA will gain marketing approval irrescpective of any AdCom or other issue (aside from primarily the FDAs review structure (and i still dont know how much weight AdCom has in that structure)...IMO Adcom yes = approval as it is just confirmation of what is proper (ie not like AdCom adds value) IMO Adcom no = limited chance of approval as it reflects basic issues with the submission (ie not like AdCom adds value) Adcom is a law (as best i know) requiring the FDA to ask for non-FDA advice...PS joint Adcom committees are kinda an animal onto themselves (as this one showed urology docs love MCNA, stats packs and chemo bombers not so much)
..i became positive to MCNA getting approval as it managed to entice some very high brow and very expert US investors to buy in...